Genprex
GNPX----
Genprex (GNPX)
Genprex, Inc., a clinical-stage gene therapy company, focuses on developing therapies for patients with cancer and diabetes. The company’s technologies are desi...
- Open
- --
- High
- --
- Low
- --
- Prev. Close
- --
- Volume
- --
- Turnover
- --
- Avg Price
- --
- Bid/Ask Ratio
- --
- Amplitude
- --
- 52wk High
- --
- Volume Ratio
- --
- Turnover Ratio
- --
Genprex Analyst Rating
View MoreForecast & Rating
Nov 19, 2024Price forecast
$8250.01105533.91%
Forecast & RatingStrong buy
1analysts
- Strong buy100.00%
- Buy0.00%
- Hold0.00%
- Sell0.00%
- Strong sell0.00%
News
- Price Alert · Jul 17 at 05:17 AM
Pre-market hot trades in US stocks: Genprex up 10.00% in pre-market; Sumitomo Mitsui Financial down 3.81% in pre-market
- Pharmaceutical Technology · Jun 23 at 04:51 AM
Genprex’s Reqorsa combo secures Canadian patent for lung cancer
- Tip Ranks · Jun 22 at 08:57 AM
Genprex Secures Canadian Patent for Reqorsa Lung Cancer Therapy
- PUBT · Jun 22 at 08:02 AM
Genprex wins Canadian patent allowance for Reqorsa combo with PD-1 or PD-L1 antibodies in lung cancer
- benzinga_article · Jun 18 at 04:06 PM
12 Health Care Stocks Moving In Thursday's After-Market Session
- PUBT · Jun 18 at 03:01 PM
Genprex shareholders approve amended 2018 equity incentive plan at annual meeting
